- Home
- UPXI vs EQ Comparison
UPXI vs EQ Comparison
Compare UPXI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | EQ |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 64.5M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UPXI | EQ |
|---|---|---|
| Price | $1.10 | $2.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.00 | $1.00 |
| AVG Volume (30 Days) | ★ 5.6M | 342.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.49 | 39.47 |
| EPS | ★ 0.76 | N/A |
| Revenue | $15,811,345.00 | ★ $41,095,000.00 |
| Revenue This Year | $118.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.22 | ★ N/A |
| Revenue Growth | N/A | ★ 13.89 |
| 52 Week Low | $0.54 | $0.29 |
| 52 Week High | $22.53 | $2.35 |
Technical Indicators
Market Signals| Indicator | UPXI | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 77.69 |
| Support Level | $0.54 | $1.22 |
| Resistance Level | $1.17 | N/A |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 80.71 | 92.57 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.